Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy

Pharmacogenetics and Genomics

Volumn 17, Issue 1, 2007, Pages 69-75

  Pae, Chi Un ^a,b   Serretti, Alessandro ^c   Mandelli, Laura ^c   De Ronchi, Diana ^c   Patkar, Ashwin A ^b   Jun, Tae Youn ^a,b   Kim, Jung Jin ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Lee, Chul ^a   Paik, In Ho ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressant; Depression; Dysbindin; Mood disorder; Pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; BINDING PROTEIN; DOSULEPIN; DYSBINDIN; DYSTROBREVIN BINDING PROTEIN 1; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; GENETIC MARKER; GENETIC REGULATION; GENETIC VARIABILITY; HAPLOTYPE; HOSPITAL PATIENT; HUMAN; KOREA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; CARRIER PROTEINS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC MARKERS; HAPLOTYPES; HUMANS; KOREA; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33846602153     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000236330.03681.6d     Document Type: Article

References (35)

1. O'Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36:467-471.
2. Pare CM, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 1962; 2:1340-1343.
3. Serretti A, Franchini L, Gasperini M, Rampoldi R, Smeraldi E. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr Scand 1998; 98:443-450.
4. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32:255-259.
5. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005; 15:61-67.
6. Benson MA, Sillitoe RV, Blake DJ. Schizophrenia genetics: dysbindin under the microscope. Trends Neurosci 2004; 27:516-519.
7. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004; 13:2699-2708.
8. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71:337-348.
9. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berlin) 2006 Jul;186(4):587-593.
10. Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su T-P, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem 2006 May 5; 281(18):12941-12949 M508157200.
11. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 2005; 31:800-805.
12. Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 2006; 32:9-16.
13. Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry 2005; 57:696-701.
14. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005; 77:918-936.
15. Kohn Y, Danilovich E, Filon D, Oppenheim A, Karni O, Kanyas K, et al. Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. Am J Med Genet B Neuropsychiatr Genet 2004; 128:65-70.
16. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72:185-190.
17. Van Den Bogaert A, Schumacher J, Schulze TG, Otte AC, Ohlraun S, Kovalenko S, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-1443.
18. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Eser D, et al. The dysbindin gene in major depression: an association study. Am J Med Genet 2004; 129B:59-63.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, District of Columbia: American Psychiatric Association; 1994.
20. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, version 2.0): New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
21. Shapira B, Lidsky D, Gorfine M, Lerer B. Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. J Clin Psychiatry 1996; 57:32-38.
22. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
23. Guy W. ECDEU Assessment manual for psychopharmacology: revised. Rockville, MD: US National Institute of Health Psychopharmacology Research Branch. U7A location and call No: Central Library Floor 2: US Government Publishers HE 20.8108:p93/2/976.
24. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25:115-121.
25. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.
26. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61:1163-1169.
27. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Minov C, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet 2003; 120B:85-89.
28. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behaviour: a comprehensive review. Curr Drug Targets (in press).
29. Kendler KS. 'A gene for...': the nature of gene action in psychiatric disorders. Am J Psychiatry 2005; 162:1243-1252.
30. Serretti A, Mandelli L, Lorenzi C, Pirovano A, Olgiati P, Colombo C, Smeraldi E. Serotonin transporter gene influences the time course of improvement of 'core' depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res (in press).
31. Cavalli Sforza L. The History and Geography of Human Genes. Princeton, New Jersey, USA: Princeton University Press; 1994.
32. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, O'Donovan MC. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005; 14:1947-1954.
33. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004; 38:577-582.
34. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11:215-219.
35. Hong Ng C, Norman TR, Naing KO, Schweitzer I, Kong Wai Ho B, Fan A, Klimidis S. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 2006; 21:87-92.